Intra-Cellular Therapies Inc
Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company that develops and commercializes therapeutics and small molecule drugs for central nervous system (CNS), neuropsychiatric, and neurological disorders. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It distributes its products through third-party wholesale drug distributors. The … Read more
Intra-Cellular Therapies Inc (ITCI) - Total Assets
Latest total assets as of December 2024: $1.37 Billion USD
Based on the latest financial reports, Intra-Cellular Therapies Inc (ITCI) holds total assets worth $1.37 Billion USD as of December 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Intra-Cellular Therapies Inc - Total Assets Trend (2011–2024)
This chart illustrates how Intra-Cellular Therapies Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Intra-Cellular Therapies Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Intra-Cellular Therapies Inc's total assets of $1.37 Billion consist of 95.6% current assets and 4.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 22.5% |
| Accounts Receivable | $166.50 Million | 12.2% |
| Inventory | $26.28 Million | 1.9% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2011–2024)
This chart illustrates how Intra-Cellular Therapies Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Intra-Cellular Therapies Inc's current assets represent 95.6% of total assets in 2024, an increase from 0.0% in 2011.
- Cash Position: Cash and equivalents constituted 22.5% of total assets in 2024, down from 58.0% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 12.2% of total assets.
Intra-Cellular Therapies Inc Competitors by Total Assets
Key competitors of Intra-Cellular Therapies Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Intra-Cellular Therapies Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Intra-Cellular Therapies Inc generates 0.50x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Intra-Cellular Therapies Inc is currently not profitable relative to its asset base.
Intra-Cellular Therapies Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.36 | 5.41 | 14.83 |
| Quick Ratio | 6.23 | 5.31 | 14.79 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.10 Billion | $ 544.25 Million | $ 429.90 Million |
Intra-Cellular Therapies Inc - Advanced Valuation Insights
This section examines the relationship between Intra-Cellular Therapies Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 12.23 |
| Latest Market Cap to Assets Ratio | 10.11 |
| Asset Growth Rate (YoY) | 87.7% |
| Total Assets | $1.37 Billion |
| Market Capitalization | $13.82 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Intra-Cellular Therapies Inc's assets at a significant premium ( 10.11x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Intra-Cellular Therapies Inc's assets grew by 87.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Intra-Cellular Therapies Inc (2011–2024)
The table below shows the annual total assets of Intra-Cellular Therapies Inc from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $1.37 Billion | +87.69% |
| 2023-12-31 | $728.29 Million | -3.51% |
| 2022-12-31 | $754.78 Million | +54.06% |
| 2021-12-31 | $489.92 Million | -31.70% |
| 2020-12-31 | $717.31 Million | +185.57% |
| 2019-12-31 | $251.19 Million | -29.68% |
| 2018-12-31 | $357.21 Million | -24.24% |
| 2017-12-31 | $471.49 Million | +21.23% |
| 2016-12-31 | $388.90 Million | -19.67% |
| 2015-12-31 | $484.10 Million | +269.23% |
| 2014-12-31 | $131.11 Million | +241.00% |
| 2013-12-31 | $38.45 Million | +93.96% |
| 2012-12-31 | $19.82 Million | -15.98% |
| 2011-12-31 | $23.59 Million | -- |